An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as Inje Cocktail; in Healthy Subjects

Trial Profile

An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as Inje Cocktail; in Healthy Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Belatacept (Primary) ; Caffeine; Dextromethorphan; Losartan; Midazolam; Omeprazole
  • Indications Anxiety disorders; Cough; Diabetic nephropathies; Gastric disorders; Gastro-oesophageal reflux; Heart failure; Hypertension; Pain; Peptic ulcer; Sleep disorders; Transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 23 Aug 2016 Results published in the British Journal of Clinical Pharmacology
    • 01 Apr 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top